LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

LLY

950.5

-2.13%↓

JNJ

221.23

+0.16%↑

ABBV

200.62

-0.79%↓

UNH

373.73

+1.81%↑

AZN

181.88

+0.21%↑

Home・Aandelen Lijst・KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc

Open

SectorGezondheidszorg

26.71 -0.04

Buy Sell

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

26.67

Max

26.73

Belangrijke statistieken
By Trading Economics
Inkomsten	55M -5.4M
Verkoop	58M 60M
EPS	0.94
Winstmarge	-8.965
Werknemers	275
EBITDA	46M -13M

Aanbevelingen
By TipRanks
Aanbevelingen	Neutraal
12 Maanden Prognose	+10.78% upside

Dividenden
By Dow Jones
Volgende Winsten	14 mei 2026

Marktinformatie
By TradingEconomics
Marktkapitalisatie	867M 1.4B
Vorige openingsprijs	26.75
Vorige sluitingsprijs	26.71

Nieuwssentiment

By Acuity

50%

166 / 347 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Strong Bearish Evidence

12.19 / 12.825 Steun & Weerstand

KalVista Pharmaceuticals Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

25 sep 2025, 17:27 UTC

Belangrijke Marktbewegers

KalVista Pharmaceuticals Shares Drop After Notes Offering Prices

7 jul 2025, 11:30 UTC

Belangrijke Marktbewegers

KalVista Pharmaceuticals Shares Rise on FDA Approval of Hereditary Angioedema Drug

31 mrt 2026, 21:33 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mrt 2026, 20:36 UTC

Acquisities, Fusies, Overnames

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

Peer Vergelijking

Prijswijziging

KalVista Pharmaceuticals Inc Prognose

Koersdoel

By TipRanks

10.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 29.6 USD 10.78%

Hoogste 35 USD

Laagste 27 USD

Gebaseerd op 8 Wall Street-analisten die 12-maands prijsdoelen bieden voor KalVista Pharmaceuticals Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Neutraal

8 ratings

Buy

Hold

Sell

Gebaseerd op 8 analisten die aandelenratings hebben gegeven aan KalVista Pharmaceuticals Inc - Dist in de afgelopen 3 maanden.

Technische score

By Trading Central

12.19 / 12.825Steun & Weerstand

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

Recent bullish events outweigh bearish events.

Sentiment

By Acuity

166 / 347 Rangschikking in Gezondheidszorg

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

Over KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE). It develops Factor XIIa, an oral inhibitor for the treatment of HAE which is in preclinical trial. In addition, the company is developing an orally disintegrating tablet formulation, including KONFIDENT-KID for pediatric use with HAE; KONFIDENT-S for adolescent and adult patients with type I or type II HAE; and KONFIDENT for a potential oral therapy for HAE attacks. The company is headquartered in Cambridge, Massachusetts.